CRDF · Cardiff Oncology, Inc.
$0.96
-0.02 (-2.13%)
At close · Aug 14
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has performed an analysis and concluded that there exists a substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$74.92M
Shares
77.80M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.96
Open$0.98
Day$0.96–1.02
52W close$0.81–3.21
Avg vol 30d1.4M
Short int12.2M · 15.7% float · 9.3d
Short vol57%
Last earningsJun 3, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 28, 2026
Est · unconfirmed
· in 15 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−47%
below
Price vs 50-day avg
−16%
below
RSI (14)
44
neutral
MACD trend
Positive
52-week position
6%
near low
Momentum
relative strength
1-month return
+9%
trailing
6-month return
−38%
trailing
YTD return
−66%
this year
Relative strength
−52%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-11% holders QoQ · +20 funds added
Insider flow
Accumulating
Net +$1.1M over 90 days · 0% sells
Short interest
Rising
15.67% of float · ▲ +0.9% MoM · 9.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
104 holders — mid 3-yr range
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
+50%
Y/Y
EPS growth
+27%
Y/Y
Free cash flow
$-38.0M
Balance sheet
$17.5M
net cash
Quant / Vol
risk profile
Volatility
84%
annualized · 1-yr
Max drawdown
−75%
past year
ATR
9.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−47%
Bearish
Price vs 50-day avg
−16%
Bearish
RSI (14)
44
Neutral
MACD trend
Positive
Bullish
52-week position
6%
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-11% holders QoQ · +20 funds added
Insider flow
Accumulating
Net +$1.1M over 90 days · 0% sells
Short interest
Rising
15.67% of float · ▲ +0.9% MoM · 9.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
104 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 6%
Range high $3
vs 200-day avg -47%
vs 50-day avg -16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRDF
this stock
Cardiff Oncology, Inc.
|
$74.92M | -65.7% | +49.6% | — | 15.7% |
|
ONC
BeOne Medicines Ltd.
|
$530.72B | +14.4% | +22179.2% | 816.0 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.25B | +11.6% | +46.2% | 30.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.16B | +4.1% | +20.8% | 19.8 | 3.3% |
|
ARGX
Argenx SE
|
$52.69B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRDF | -2.7% | +9.4% | -38.3% | +12.0% | -65.7% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -3.1% | +5.0% | -52.0% | +8.1% | -79.6% |
Key facts
CIK
1213037
CUSIP
14147L108
13F (30d)
99 filings
97 filers
Visit website
Investor relations